12-Jun-2026
No headlines found.
Globe Newswire (Tue, 12-May 8:00 AM ET)
OPKO Health Expands Nicoya Agreement to Support RAYALDEE Commercialization in Greater China
Globe Newswire (Thu, 30-Apr 8:30 AM ET)
Globe Newswire (Thu, 30-Apr 8:00 AM ET)
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
Globe Newswire (Tue, 28-Apr 4:05 PM ET)
Globe Newswire (Wed, 22-Apr 8:00 AM ET)
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
Globe Newswire (Tue, 21-Apr 4:05 PM ET)
OPKO Health's ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
Globe Newswire (Wed, 8-Apr 8:00 AM ET)
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Opko Health trades on the NASDAQ stock market under the symbol OPK.
As of June 12, 2026, OPK stock price declined to $1.42 with 1,701,120 million shares trading.
OPK has a beta of 1.28, meaning it tends to be more sensitive to market movements. OPK has a correlation of 0.17 to the broad based SPY ETF.
OPK has a market cap of $1.07 billion. This is considered a Small Cap stock.
Last quarter Opko Health reported $124 million in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-7 million and met earnings estimates .
In the last 3 years, OPK traded as high as $2.24 and as low as $.85.
The top ETF exchange traded funds that OPK belongs to (by Net Assets): IWM, VTI, VB, VXF, IWN.
OPK has underperformed the market in the last year with a price return of +6.0% while the SPY ETF gained +24.1%. However, in the short term, OPK had mixed performance relative to the market. It has outperformed in the last 3 months, returning +22.4% vs +11.6% return in SPY. But in the last 2 weeks, OPK shares have been beat by the market, returning -2.7% compared to an SPY return of -1.9%.
OPK support price is $1.40 and resistance is $1.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OPK shares will trade within this expected range on the day.